EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis

Clinical Cancer Research

Volumn 22, Issue 18, 2016, Pages 4585-4593

  Gainor, Justin F ^a   Shaw, Alice T ^a   Sequist, Lecia V ^a   Fu, Xiujun ^a   Azzoli, Christopher G ^a   Piotrowska, Zofia ^a   Huynh, Tiffany G ^a   Zhao, Ling ^a   Fulton, Linnea ^a   Schultz, Katherine R ^a   Howe, Emily ^a   Farago, Anna F ^a   Sullivan, Ryan J ^a   Stone, James R ^a   Digumarthy, Subba ^a   Moran, Teresa ^b   Hata, Aaron N ^a   Yagi, Yukako ^a   Yeap, Beow Y ^a   Engelman, Jeffrey A ^a   Mino Kenudson, Mari ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ATEZOLIZUMAB; CD8 ANTIGEN; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOKING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; WILD TYPE; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENE TRANSLOCATION; GENETICS; GENOTYPE; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84990938506     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-3101     Document Type: Article

References (27)

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
2. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. Firstline crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
3. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. JClin Oncol 2013;31:3987-96.
4. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ,Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006.
5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
6. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-67.
7. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
8. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-smallcell lung cancer. N Engl J Med 2015;373:123-35.
9. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
10. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015 Dec 18. [Epub ahead of print].
11. Spira A, Park K, Mazieres J, Vansteenkistie JF, Rittmeyer A, BallingerM, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol 33, 2015(suppl; abstr 8010).
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
13. Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 2015;28: 1154-66.
14. Dahlin AM, HenrikssonML, Van Guelpen B, Stenling R, Oberg A, Rutegard J, et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011;24:671-82.
15. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky V, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146-58.
16. GettingerSN,HornL,Gandhi L,SpigelDR,Antonia SJ, RizviNA, et al.Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004-12.
17. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
18. Kerr K, Tsao M, Nicholson A, Yatabe Y, Wistuba I, Hirsch F. PD-L1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015;10:985-9.
19. Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
20. Marzec M, Zhang Q, Goradia A, Raqhunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008;105:20852-7.
21. Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 2015;21:4014-21.
22. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
23. Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFRDriven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol 2015;10: 910-23.
24. Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 2015;6:14209-19.
25. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61.
26. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
27. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and neversmokers. Cell 2012;150:1121-34.